Dr. Armaghany on the Utility of ctDNA in CRC
Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.
Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC
Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.
Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC
Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.
Dr. Armaghany on Gene Sequencing in CRC
Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512